don't you mean smoke and mirrors ?
Printable View
As in the increased sales into ever increasing receivables to their subsequent reversal & restatements?
To me, PEB violated every underlying accounting principles of conservatism, accrual & recognition of revenues which could be violated!
But hi, who are we to comment when the institutions (who are sooooo smart) have no issue?
Guess the difference is that we weren’t playing with other peoples’ monies and lose via the ever lower priced underwritings!
Balance, contrary to other posters, I think you have saved investors many thousands by highlighting ****ty business practices especially in this company. We all want PEB to succeed but the company continually glosses over the hard yards required to get traction in USA. Raising $150M and targetting the USA does not mean you will be a success.
I would of preferred the company test out some assumptions and then go big (raise $). Common mistake from our companies.
P.S interested in Chelsea's next report on valuation.
To me, this is the tragedy for NZ inc and all the biomed & biotech companies out there looking for funding.
PEB could have been a poster boy (like Cochlear on ASX) for success and attract more investors to support our biotech & biomed industry (always short of funding) - instead PEB has squandered over $200m of precious fundings, and given the industry a bad bad name through woeful execution, and unbelievably bullish but unfulfilled promises and expectations to raise the funding.
The big thing I've always been confused about is why they made the decision to commercialise the IP by trying to sell the tests directly (higher $ but higher risk/cost). Rather than licensing the genetic IP to Roche, Qiagen etc or even just sell the genetic kits via incumbant distribution channels to be analysed by 3rd parties. They would still face the regulartory challenges but the operational cost (and distraction) would have been significantly reduced and saved alot of capital. Any insight from maybe historical reports?
4 years and half years ago - DD sure knew how to feed the chooks (ready for the next rights issue?).
https://www.nbr.co.nz/article/pacifi...ng-cs-p-161995
"Cancer diagnostics company Pacific Edge [NZX: PEB] is probably being closely watched by bigger US medical companies waiting for a ripe opportunity to acquire, its chief executive David Darling believes."
September 2014
Then, there's the 'several tens of thousands of tests' comment by Chairman Swan (never retracted) in Dec 2013.
And guess who sold shares in 2014 after all the bullish comments?
[QUOTE=Balance;755919]
https://www.nbr.co.nz/article/pacifi...ng-cs-p-161995
"Cancer diagnostics company Pacific Edge [NZX: PEB] is probably being closely watched by bigger US medical companies waiting for a ripe opportunity to acquire, its chief executive David Darling believes."
September 2014
[QUOTE]
The small market cap and open share register {{{could}}} make PEB a prime takeover target. Five years of no interest from any of the big med companies... what's that saying?
Had a quick look at their cash position and they are getting down to their last funds? $10M @ Sep 2018 and burning $9M a half? They might have another $7M lying around but its going fast.
Why is this valued @ $135M?
Potential.
Why is Cuv worth 1.1 billion
Why is Nxs worth 143 mil up 37.5% on IPO
Why is MDX worth 100 mil USD
NXS and MDX burn more cash.
High risk, high reward.